Welcome to our dedicated page for Lifemd news (Ticker: LFMDP), a resource for investors and traders seeking the latest updates and insights on Lifemd stock.
LifeMD, Inc. 8.875% Series A Cumulative Perpetual Preferred Stock (symbol: LFMDP) is backed by a company that offers a comprehensive telemedicine solution connecting physicians, medical providers, pharmacists, and patients worldwide. Their platform is HIPAA-compliant and encrypted, allowing for secure interactions and management of medical conditions. In addition to telehealth services, they also provide mobile diagnostic telehealth equipment and sell nutritional supplements and over-the-counter products. With a focus on virtual primary care, LifeMD is committed to providing accessible, high-quality healthcare services.
LifeMD, Inc. (NASDAQ: LFMD) announced it will release its financial results for the year ending December 31, 2021, on March 7, 2022, after market close. The company will hold a conference call at 4:30 PM ET to discuss these results and provide a corporate update. LifeMD is a growing telehealth company offering virtual care across 50 states, utilizing a proprietary tech platform and pharmacy network to enhance healthcare accessibility.
LifeMD announced the nationwide launch of its virtual primary care platform, providing 24/7 access to affordable healthcare across all 50 states. This platform enables patients to connect with top-quality doctors through a simple three-step process: completing a health questionnaire, a virtual consultation, and ongoing access to care. With significant investments in technology and strategic partnerships, LifeMD aims to enhance healthcare access and efficiency. Previously available in beta, the platform targets the 25% of U.S. adults lacking a primary care physician.
LifeMD, a prominent telehealth company, will participate in two key conferences: the SVB Leerink Global Healthcare Conference from February 16-18, 2022, and Citi’s Virtual Healthcare Conference on February 23-24, 2022. Interested parties can request one-on-one meetings at the SVB conference via a provided link. LifeMD offers accessible telehealth services across 50 states, focusing on various healthcare needs through its advanced technology platform and nationwide pharmacy network. For more information, visit LifeMD.com.
LifeMD, Inc. (NASDAQ: LFMD) anticipates FY2022 revenue between $142 million and $148 million, reflecting a robust year-over-year growth of 149% with a fourth quarter revenue of $27.4 million. The company aims to achieve Adjusted EBITDA profitability by Q4 2022. CEO Justin Schreiber highlighted increasing demand for telehealth services and the launch of LifeMD Virtual Primary Care. CFO Marc Benathen noted progress in reducing cash burn and maintaining liquidity to support growth initiatives.
LifeMD announced management participation at the virtual BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference from February 15-17, 2022. Investors interested in one-on-one meetings can register here. LifeMD is a direct-to-patient telehealth provider offering virtual medical care and prescription delivery across the U.S.
LifeMD has announced its acquisition of Cleared, a prominent telehealth platform specializing in allergy, asthma, and immunology treatments. The deal, valued at approximately $3.9 million, aims to enhance LifeMD's offerings and drive growth in the $13.5 billion U.S. allergy market. With more than 75 million Americans affected by allergies, this acquisition is expected to synergize with LifeMD's existing services and expand its patient base. The acquisition is anticipated to be accretive to LifeMD's Adjusted EBITDA in 2022, marking a significant step in its strategic growth.
LifeMD, Inc. (NASDAQ: LFMD) announced key executive appointments aimed at enhancing its telehealth services. Dennis Wijnker joins as CTO, bringing over 20 years in software development from Doctor Evidence, while Garett Hunter takes on the role of SVP and GM of LifeMD Primary Care, previously serving at Yumi. Their expertise in technology and marketing is expected to play a crucial role in the upcoming launch of LifeMD’s virtual primary care platform. Both received equity awards as part of their compensation packages.
LifeMD, Inc. (NASDAQ: LFMD) announced its participation in three investor conferences and one panel event in January 2022, providing opportunities for one-on-one investor meetings. Key dates include the LifeSci Partners Corporate Access Event from January 5-7, the H.C. Wainwright Bioconnect Virtual Conference on January 10 with an on-demand presentation starting at 7:00 am ET, and the Sidoti Virtual Small Cap Conference on January 19-20. LifeMD specializes in direct-to-patient telehealth services across all 50 states, offering virtual access to affordable medical care.
CEO Schreiber to discuss changes made possible via proprietary virtual care platforms
LifeMD, a leading telehealth company (NASDAQ: LFMD), announced that CEO Justin Schreiber will participate in a panel at the LifeSci Partners Corporate Access Event, happening virtually from January 5-7, 2022. Schreiber will discuss how LifeMD's virtual care technology is transforming healthcare to improve affordability and patient outcomes. The panel, titled 'Telehealth & Digital Medicine: At a Crossroads of Virtual Care,' is scheduled for January 6 at 8:30 am ET. Interested parties can register for the webcast to view the discussion.
On December 23, 2021, LifeMD announced a cash dividend of $0.622483 per share for its 8.875% Series A Cumulative Perpetual Preferred Stock (LFMDP), payable on January 14, 2022. The dividend will be distributed to shareholders of record on January 4, 2022. LifeMD is a growing telehealth company providing virtual medical care across the U.S., emphasizing affordable treatment and home delivery of prescriptions.
FAQ
What is the current stock price of Lifemd (LFMDP)?
What does LifeMD, Inc. offer?
Is LifeMD's platform secure?
What products does LifeMD sell?
What is the focus of LifeMD's services?
How does LifeMD contribute to the healthcare industry?
